FILE:LH/LH-8K-20050315103921.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On March 14, 2005  Laboratory Corporation of America Holdings (LabCorp) announced that Executive Vice President for Corporate Affairs, Bradford T. Smith, is scheduled to speak at the SG Cowen & Company Healthcare Conference in Boston, MA on March 15, 2005 at 10:30 a.m. and 11:20 a.m. Eastern Time.
Exhibits
99.1 Press Release dated March 14, 2005
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1
Laboratory Corporation of America Holdings 358 South Main Street Burlington, NC 27215 Telephone:(336) 584-5171
FOR IMMEDIATE RELEASE Contact: Brad Hayes Shareholder Direct: (800)LAB-0401 Company Information: www.LabCorp.com
Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that Executive Vice President for Corporate Affairs, Bradford T. Smith, is scheduled to speak at the SG Cowen & Company Healthcare Conference in Boston, MA on March 15, 2005 at 10:30 a.m. and 11:20 a.m. Eastern Time.
Burlington, NC, March 14, 2005 
A live audio webcast of the presentation will be available via the Company web site at . An archived replay of the audio webcast will be available.
www.labcorp.com
Laboratory Corporation of America Holdings, an S&P 500 company with a BBB investment-grade credit rating, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $3.1 billion in 2004, approximately 23,500 employees nationwide, and more than 220,000 clients, LabCorp offers over 4,400 clinical assays ranging from blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON , Inc. based in Stratford, CT, and US LABS based in Irvine, CA. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our web site at: www.LabCorp.com.
About LabCorp
Systems
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2004 and subsequent SEC filings.


